Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy

Cancer Letters

Volumn 371, Issue 1, 2016, Pages 117-124

  Ramachandran, Indu R ^a,b   Condamine, Thomas ^a,b   Lin, Cindy ^a   Herlihy, Sarah E ^a   Garfall, Alfred ^c   Vogl, Dan T ^c   Gabrilovich, Dmitry I ^a,b   Nefedova, Yulia ^a,b  

^a WISTAR INSTITUTE   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Chemoresistance; Multiple myeloma; Myeloid derived suppressor cells; Neutrophils

Indexed keywords

DOXORUBICIN; MELPHALAN; ALKYLATING AGENT; ANTINEOPLASTIC ANTIBIOTIC;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL COUNT; CELL GROWTH; CELL INTERACTION; CELL ISOLATION; CELL LINEAGE; CELL MANIPULATION; CELL POPULATION; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; TARGET CELL; TUMOR MICROENVIRONMENT; ANIMAL; APOPTOSIS; BONE MARROW CELL; C57BL MOUSE; COCULTURE; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; PARACRINE SIGNALING; PATHOLOGY; PHENOTYPE; TIME FACTOR; TUMOR CELL CULTURE; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; CELL LINE, TUMOR; CELL LINEAGE; COCULTURE TECHNIQUES; DISEASE MODELS, ANIMAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HUMANS; MELPHALAN; MICE, INBRED C57BL; MULTIPLE MYELOMA; MYELOID CELLS; NEUTROPHILS; PARACRINE COMMUNICATION; PHENOTYPE; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT;

EID: 84951768535     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.10.040     Document Type: Article

References (30)

1. -/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scand. J. Immunol 2010, 72:540-547.
2. Favaloro J., Liyadipitiya T., Brown R., Yang S., Suen H., Woodland N., et al. Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma. Leuk. Lymphoma 2014, 12:1-8.
3. Gorgun G., Whitehill G., Anderson J., Hideshima T., Maguire C., Laubach J., et al. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood 2013, 121:2975-2987.
4. Ramachandran I., Martner A., Pisklakova A., Condamine T., Chase T., Vogl T., et al. Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow. J. Immunol 2013, 190:3815-3823.
5. Van Valckenborgh E., Schouppe E., Movahedi K., De Bruyne E., Menu E., De Baetselier P., et al. Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow. Leukemia 2012, 26:2424-2428.
6. Gabrilovich D., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol 2009, 9:162-174.
7. Abe M., Hiura K., Wilde J., Shioyasono A., Moriyama K., Hashimoto T., et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 2004, 104:2484-2491.
8. Chauhan D., Singh A., Brahmandam M., Carrasco R., Bandi M., Hideshima T., et al. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell 2009, 16:309-323.
9. Nair J., Carlson L., Koorella C., Rozanski C., Byrne G., Bergsagel P., et al. CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment. J. Immunol 2011, 187:1243-1253.
10. Nefedova Y., Landowski T., Dalton W. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 2003, 17:1175-1182.
11. Zheng Y., Cai Z., Wang S., Zhang X., Qian J., Hong S., et al. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood 2009, 114:3625-3628.
12. Condamine T., Kumar V., Ramachandran I., Youn J., Celis E., Finnberg N., et al. ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. J. Clin. Invest 2014, 124:2626-2639.
13. Liu F., Song Y., Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999, 7:1258-1266.
14. Takebe Y., Seiki M., Fujisawa J., Hoy P., Yokota K., Arai K., et al. SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. Mol. Cell. Biol 1988, 8:466-472.
15. Cheung W., Kim J., Linden M., Peng L., Van Ness B., Polakiewicz R., et al. Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice. J. Clin. Invest 2004, 113:1763-1773.
16. Damiano J.S., Cress A.E., Hazlehurst L.A., Shtil A.A., Dalton W.S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999, 93:1658-1667.
17. Zheng Y., Yang J., Qian J., Qiu P., Hanabuchi S., Lu Y., et al. PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma. Leukemia 2013, 27:702-710.
18. Bachelot T., Ray-Coquard I., Menetrier-Caux C., Rastkha M., Duc A., Blay J. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br. J. Cancer 2003, 88:1721-1726.
19. Dedoussis G., Mouzaki A., Theodoropoulou M., Menounos P., Kyrtsonis M., Karameris A., et al. Endogenous interleukin 6 conveys resistance to cis-diamminedichloroplatinum-mediated apoptosis of the K562 human leukemic cell line. Exp. Cell Res 1999, 249:269-278.
20. Frankel A., Mills G. Peptide and lipid growth factors decrease cis-diamminedichloroplatinum-induced cell death in human ovarian cancer cells. Clin. Cancer Res 1996, 2:1307-1313.
21. Voorzanger-Rousselot N., Favrot M., Blay J. Resistance to cytotoxic chemotherapy induced by CD40 ligand in lymphoma cells. Blood 1998, 92:3381-3387.
22. Wang Y., Niu X., Qu Y., Wu J., Zhu Y., Sun W., et al. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett 2010, 295:110-123.
23. Wang Y., Qu Y., Niu X., Sun W., Zhang X., Li L. Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cytokine 2011, 56:365-375.
24. Hideshima T., Nakamura N., Chauhan D., Anderson K. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 2001, 20:5991-6000.
25. Xu F., Gardner A., Tu Y., Michl P., Prager D., Lichtenstein A. Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors. Br. J. Haematol 1997, 97:429-440.
26. Menzel T., Rahman Z., Calleja E., White K., Wilson E., Wieder R., et al. Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine. Blood 1996, 87:1056-1063.
27. Iclozan C., Antonia S., Chiappori A., Chen D., Gabrilovich D. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol. Immunother 2013, 62:909-918.
28. Ramakrishnan R., Antonia S., Gabrilovich D. Combined modality immunotherapy and chemotherapy: a new perspective. Cancer Immunol. Immunother 2008, 57:1523-1529.
29. Ramakrishnan R., Gabrilovich D. Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer. Cancer Immunol. Immunother 2011, 60:419-423.
30. Ramakrishnan R., Gabrilovich D. Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer. Cancer Immunol. Immunother 2013, 62:405-410.